Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI) presented updated data from the Phase 2 ESSENTIAL study on selinexor for myelofibrosis patients at the ASH 2021 Annual Meeting. Results revealed that 40% of patients achieved a spleen volume reduction (SVR) of at least 35%, and 60% experienced an SVR of at least 25% after 24 weeks of treatment. The drug exhibited a favorable safety profile with manageable side effects. Additionally, the company has initiated a new Phase 2 study comparing selinexor to physician's choice in previously treated myelofibrosis patients.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the appointment of Peter K Honig, MD, MPH, to its Board of Directors effective December 3, 2021. Dr. Honig brings over 30 years of experience in drug development from leadership roles at Pfizer, Merck, and the FDA. He replaces Mikael Dolsten, who stepped down on December 2, 2021, due to competing demands. Dr. Honig expressed enthusiasm for contributing to Karyopharm's growth and advancing its cancer therapies. The company is focused on pioneering novel cancer treatments, including its lead drug, XPOVIO®.

Karyopharm Therapeutics (KPTI) has commenced a Phase 2 study (XPORT-MF-035) to assess the efficacy of oral selinexor in myelofibrosis patients previously treated with JAK inhibitors. The trial aims to enroll up to 112 patients, evaluating the primary endpoint of spleen volume reduction. This study follows promising results from the ESSENTIAL trial, where 33% of patients experienced significant SVR after 24 weeks of treatment. The company emphasizes its commitment to addressing unmet medical needs in serious conditions like myelofibrosis.

Karyopharm Therapeutics (Nasdaq: KPTI) announced the completion of patient recruitment for the Phase 3 SIENDO study, evaluating selinexor for front-line maintenance therapy in advanced or recurrent endometrial cancer. With over 250 patients enrolled, the study aims to show improved progression-free survival rates. There are currently no approved maintenance therapies for this cancer type. Karyopharm expects to report top-line data by year-end 2021 or early 2022, which could demonstrate selinexor's therapeutic potential and impact future treatment options.

Karyopharm Therapeutics (Nasdaq: KPTI) announced on December 1, 2021, that its Compensation Committee granted stock options for 68,900 shares to 13 new employees, effective November 30, 2021. The options have an exercise price of $6.95 per share, equal to the closing price on the grant date. Each option vests over four years, with 25% vesting after one year, and can be exercised immediately upon termination under certain conditions. This move is part of Karyopharm's strategy to attract talent as it develops novel cancer therapies.

Karyopharm Therapeutics (Nasdaq: KPTI) will host a virtual Investor Day on December 8, 2021, from 10:00 a.m. to 12:30 p.m. ET. The event will feature Karyopharm's executive team and six experts in oncology to discuss commercial opportunities and pipeline priorities. Attendees can join via phone or view a live webcast on the company’s website. Karyopharm specializes in cancer therapies, notably its lead drug XPOVIO®, approved for several hematologic cancers. The event aims to outline the company's vision and milestones.

Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in the Jefferies London Healthcare Conference with CEO Richard Paulson hosting a fireside chat. The discussion will be available for on-demand listening starting November 18, 2021, at 3:00 a.m. Eastern Time. A replay will be accessible for 30 days on the company's investor website.

Karyopharm is focused on developing innovative cancer therapies, particularly through its XPOVIO® (selinexor) compound, which is approved for multiple hematologic malignancies.

Karyopharm Therapeutics (KPTI) announced new data from a Phase 2 study of selinexor, an oral SINE compound for myelofibrosis patients previously treated with JAK inhibitors. The study showed a 33% response rate, with significant spleen volume reduction and improved anemia status. Despite ruxolitinib's poor prognosis (14 months survival), selinexor demonstrated durable responses and a well-tolerated safety profile. Karyopharm plans to initiate a new Phase 2 study evaluating selinexor against physician's choice in late 2021. Results will be presented at the ASH 2021 meeting from December 11-14.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported third-quarter 2021 financial results, revealing net product revenue of $26.7 million, a 32% increase from the previous quarter and 25% growth year-over-year. The company highlighted its commercial success with XPOVIO, moving into earlier treatment lines for multiple myeloma. R&D expenses rose to $45.8 million, while the net loss was $51.8 million or $0.69 per share. Karyopharm expects a cash runway into mid-2023, with key upcoming milestones including Phase 3 data from the SIENDO study in endometrial cancer.